Background: Stroke is a leading cause of mortality and disability globally, with acute ischemic strokes(AIS) due to Large Vessel Occlusion (LVO) presenting significant treatment challenges. Mechanical thrombectomy (MT) has emerged as an effective intervention for AIS within an 8-hour window from symptom onset. However, the potential to extend this window up to 24 hours for select patients could revolutionize outcomes for those arriving late at comprehensive stroke centers. This study investigates the efficacy and safety of Cerebrolysin as an adjunct therapy to MT in extended time window and improving patient recovery. Methods: We conducted a multi-center, prospective, randomized study within the Chang Gung Memorial Hospital system in Taiwan, targeting 100 AIS patients eligible for MT beyond the traditional 8-hour window. Participants were randomized to receive either standard care or Cerebrolysin post-MT, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery. Results: The primary outcome will measure the proportion of patients achieving favorable functional outcomes (modified Rankin Scale 0-2) at 90 days. Secondary outcomes include the impact of Cerebrolysin on secondary hemorrhagic transformation, brain edema, mortality rates, and quality of life. The study aims to provide comprehensive data on the benefits of adding Cerebrolysin to the standard post-MT care, focusing on its potential to protect against reperfusion injuries and maintain blood-brain barrier integrity. Conclusion: By evaluating the role of Cerebrolysin in conjunction with MT, this study aims to extend the therapeutic window for AIS treatment, offering hope for improved outcomes for patients who would otherwise be ineligible for current reperfusion therapies. The findings may pave the way for new guidelines in stroke management, emphasizing the importance of integrated care approaches in enhancing patient recovery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
Functional Recovery and Complication Rates Post-Thrombectomy
This study will assess functional recovery primarily through the proportion of subjects achieving a favorable outcome as defined by an mRS score of 0-2. Secondary measures of efficacy will include changes in NIHSS scores at acute (day 0), subacute (day 1), and early convalescent (day 7) phases post-stroke. The incidence of complications such as secondary intracranial hemorrhage (ICH) or hemorrhage transformation (HT), as well as brain edema with midline shift, will be monitored. Mortality rates and functional independence, measured by the Barthel Index, will be evaluated to provide a comprehensive assessment of patient recovery and treatment impact.
Time frame: mRS at 90 days and 12 months; NIHSS at 0, 1, and 7 days; mortality and Barthel Index at 90 days and 12 months post-stroke.
Imaging and High cortical Functional Assessment Endpoints
Secondary outcomes will include imaging endpoints to measure the impact of Cerebrolysin on cerebral tissue preservation, specifically evaluating final infarct volume, infarct growth, and penumbral salvage. Functional assessments will track changes in language function using the 15-item Boston Naming Test, global cognitive function via the Montreal Cognitive Assessment, and mood disturbances with the Hamilton Depression Rating Scale. These assessments will collectively inform on the neuroprotective effects of Cerebrolysin.
Time frame: Imaging endpoints will be quantified at 30 days (1 month) and at 90 days (3 months) post-stroke. For functional and mood assessments within the Cerebrolysin group, evaluations will be precisely scheduled at 30 days post-stroke to establish early recovery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.